Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels

EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection

(2015)   JOURNAL OF HEPATOLOGY

Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B

(2012) Milan J. Sonneveld et al.   HEPATOLOGY

Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype

(2011) Milan J Sonneveld et al.   ANTIVIRAL THERAPY

Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis B

(2011) Milan J. Sonneveld et al.   GASTROENTEROLOGY

Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?

(2011) Harry L A Janssen et al.   GUT

Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C

(2011) Y.-F. Liaw et al.   HEPATOLOGY

A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B

(2011) Milan J. Sonneveld et al.   JOURNAL OF CLINICAL VIROLOGY

Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report

(2011) Henry Lik-Yuen Chan et al.   JOURNAL OF HEPATOLOGY

Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B

(2010) Vincent Wai-Sun Wong et al.   HEPATOLOGY

Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline

(2010) Milan J. Sonneveld et al.   HEPATOLOGY

Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all hepatitis B e antigen-positive patients

(2010) Teerha Piratvisuth et al.   HEPATOLOGY

Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment

(2010) Bettina E. Hansen et al.   JOURNAL OF MEDICAL VIROLOGY

Factors That Predict Response of Patients With Hepatitis B e Antigen–Positive Chronic Hepatitis B to Peginterferon-Alfa

(2009) Erik H.C.J. Buster et al.   GASTROENTEROLOGY

Chronic hepatitis B: Update 2009

(2009) Anna S. F. Lok et al.   HEPATOLOGY

Sustained HBeAg and HBsAg Loss After Long-term Follow-up of HBeAg-Positive Patients Treated With Peginterferon α-2b

(2008) Erik H.C.J. Buster et al.   GASTROENTEROLOGY

HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B

(2008) Michael W. Fried et al.   HEPATOLOGY